Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 in Children and Young Adults With Rett Syndrome
NCT07257978Phase 3Not yet recruiting
- Sponsor
- Fenix Innovation Group
- Start
- Jul 2027
- Primary completion
- Oct 2028
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
A Phase 3 trial of NTI164 in Rett syndrome (RTT), sponsored by Fenix Innovation Group. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
NTI164
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT07257978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257978.